ACRV (STOCKS)
Acrivon Therapeutics, Inc. Common Stock
$1.520000
+0.040000 (+2.70%)
Prev close: $1.480000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Peter Blume-Jensen
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $65.70M
- Employees
- 78
- P/E (TTM)
- -0.74
- P/B (TTM)
- 0.60
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $5.09M |
| Operating Expenses | $82.35M |
| Research and Development | $59.74M |
| Other Operating Expenses | $22.61M |
| Operating Income/Loss | -$82.35M |
| Income/Loss From Continuing Operations After Tax | -$77.19M |
| Income/Loss From Continuing Operations Before Tax | -$77.19M |
| Net Income/Loss | -$77.27M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$77.27M |
| Net Income/Loss Available To Common Stockholders, Basic | -$77.27M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.00 |
| Diluted Earnings Per Share | -$2.00 |
| Basic Average Shares | 38,883,640 |
| Diluted Average Shares | 38,883,640 |
| Assets | $107.83M |
| Current Assets | $99.22M |
| Noncurrent Assets | $8.61M |
| Fixed Assets | $4.65M |
| Other Non-current Assets | $3.96M |
| Liabilities | $12.32M |
| Current Liabilities | $11.05M |
| Accounts Payable | $1.16M |
| Other Current Liabilities | $9.89M |
| Noncurrent Liabilities | $1.26M |
| Equity | $95.52M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $95.52M |
| Liabilities And Equity | $107.83M |
| Net Cash Flow From Operating Activities | -$64.67M |
| Net Cash Flow From Operating Activities, Continuing | -$64.67M |
| Net Cash Flow From Investing Activities | $60.01M |
| Net Cash Flow From Investing Activities, Continuing | $60.01M |
| Net Cash Flow From Financing Activities | -$439.00K |
| Net Cash Flow From Financing Activities, Continuing | -$439.00K |
| Net Cash Flow | -$5.09M |
| Net Cash Flow, Continuing | -$5.09M |
| Comprehensive Income/Loss | -$77.37M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$77.37M |
| Other Comprehensive Income/Loss | -$18.34M |